文献速递腹部CTMRPET

胰腺导管腺癌治疗反应评估:影像学的作用

Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

胰腺导管腺癌(PDAC)5年生存率低,新辅助化疗和放疗后需评估治疗反应,但传统RECIST因肿瘤形态和组织学复杂而受限,新辅助治疗后可切除性判断仍是挑战。本文综述PDAC治疗反应评估的挑战与局限,并回顾新型形态学和功能影像工具应用价值的现有证据。

要点

  • 传统RECIST在PDAC治疗反应评估中作用有限,尤其对局部区域和全身治疗的反应评估。
  • 新辅助治疗后肿瘤可切除性的判断仍是临床挑战。
  • 新型形态学和功能影像工具在PDAC治疗反应评估中的价值尚需进一步证据支持。

核心结论

  • 传统RECIST在PDAC治疗反应评估中作用有限,新型形态学和功能影像工具在该病中的应用价值需进一步研究。

研究设计与样本

  • 综述,总结PDAC治疗反应评估的挑战与局限,并回顾新型形态学和功能影像工具应用价值的现有证据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive gastrointestinal (GI) malignancy with poor 5-year survival rate. Advances in surgical techniques and introduction of novel combination chemotherapy and radiation therapy regimens have necessitated the need for biomarkers for assessment of treatment response. Conventional imaging methods such as RECIST have been used for response evaluation in clinical trials particularly in patients with metastatic PDAC. However, the role of these approaches for assessing response to loco-regional and systemic therapies is limited due to complex morphological and histological nature of PDAC. Determination of tumor resectability after neoadjuvant therapy remains a challenge. This review article provides an overview of the challenges and limitations of response assessment in PDAC and reviews the current evidence for the utility of novel morphological and functional imaging tools in this disease.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Baliyan V, Kordbacheh H, Parakh A, et al. Response assessment in pancreatic ductal adenocarcinoma: role of imaging. Abdom Radiol (NY). 2018. PMID: 29243123. doi:10.1007/s00261-017-1434-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。